Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

S 531011

Next Previous
Drug Profile

S 531011

Alternative Names: S-531011

Latest Information Update: 19 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CCR8 receptor antagonists; Regulatory T-lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 30 May 2025 Efficacy, pharmacokinetics, pharmacodynamics and adverse events data from a phase-I/II aCCeleR8-001 trial in solid tumours presented at 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 12 Nov 2021 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA, Japan (IV) (NCT05101070) (Shionogi pipeline, November 2021)
  • 12 Nov 2021 Phase-I/II clinical trials in Solid tumours (Monotherapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA, Japan (IV) (NCT05101070)(Shionogi pipeline, November 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top